A function-blocking PAR4 antibody is markedly antithrombotic in the face of a hyperreactive PAR4 variant

Thrombin activates human platelets via 2 protease-activated receptors (PARs), PAR1 and PAR4, both of which are antithrombotic drug targets: a PAR1 inhibitor is approved for clinical use, and a PAR4 inhibitor is in trial. However, a common sequence variant in human PAR4 (rs773902, encoding Thr120 in...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: French, Shauna L., Thalmann, Claudia, Bray, Paul F., Macdonald, Lynn E., Murphy, Andrew J., Sleeman, Mark W., Hamilton, Justin R.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2018
Témata:
Thrombosis and Hemostasis
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5998926/
https://ncbi.nlm.nih.gov/pubmed/29884748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017015552
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky